Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Poxel : premiers résultats positifs dans la NASH | Zone bourse
09:28am, Wednesday, 24'th Jun 2020
Pour recevoir l'information de POXEL en temps réel, faites-en la demande à [email protected]
Critical Contrast: GENFIT S A/ADR (GNFT) and Its Peers
01:36am, Wednesday, 24'th Jun 2020
GENFIT S A/ADR (NASDAQ: GNFT) is one of 141 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare GENFIT S A/AD
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, in
ENDRA Life Sciences Expands IP Portfolio to 72 with Addition of Key Patents | | IT Business Net
03:11pm, Tuesday, 23'rd Jun 2020
Two Newly Issued Patents Further Protect ENDRA's TAEUS Platform Capabilities ANN ARBOR, MI / ACCESSWIRE / June 23, 2020 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a
Fate of Intercept's NASH drug clouded by murky FDA review delays
01:49pm, Tuesday, 23'rd Jun 2020
The agency had planned to announce its decision on whether or not to approve the first treatment for the fatty liver disease known as NASH this week.
